| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pre-Eclampsia | 10 | 2022 | 246 | 3.520 |
Why?
|
| Hypertension, Pregnancy-Induced | 6 | 2021 | 69 | 2.460 |
Why?
|
| Activins | 4 | 2022 | 26 | 2.420 |
Why?
|
| Cardiomyopathies | 8 | 2018 | 240 | 2.100 |
Why?
|
| Patient Readmission | 4 | 2019 | 329 | 2.000 |
Why?
|
| Echocardiography | 13 | 2021 | 911 | 1.880 |
Why?
|
| Ventricular Function, Left | 4 | 2022 | 592 | 1.660 |
Why?
|
| Sepsis | 5 | 2018 | 306 | 1.570 |
Why?
|
| Postpartum Period | 3 | 2021 | 135 | 1.500 |
Why?
|
| Heart Diseases | 4 | 2022 | 290 | 1.400 |
Why?
|
| Heart Ventricles | 4 | 2021 | 760 | 1.360 |
Why?
|
| Pregnancy | 21 | 2022 | 2894 | 1.310 |
Why?
|
| Pregnancy Complications, Cardiovascular | 3 | 2017 | 104 | 1.280 |
Why?
|
| Perioperative Care | 7 | 2022 | 161 | 1.250 |
Why?
|
| Opioid-Related Disorders | 2 | 2019 | 161 | 1.080 |
Why?
|
| Shock, Cardiogenic | 3 | 2018 | 95 | 1.060 |
Why?
|
| Anesthesiology | 8 | 2022 | 157 | 1.050 |
Why?
|
| Ventricular Dysfunction, Left | 3 | 2019 | 318 | 1.000 |
Why?
|
| Blood Pressure | 4 | 2018 | 1143 | 0.960 |
Why?
|
| Biomedical Research | 2 | 2018 | 376 | 0.900 |
Why?
|
| Stroke Volume | 3 | 2022 | 456 | 0.880 |
Why?
|
| Peripartum Period | 2 | 2019 | 20 | 0.870 |
Why?
|
| Critical Care | 4 | 2020 | 370 | 0.840 |
Why?
|
| Shock, Septic | 4 | 2018 | 102 | 0.820 |
Why?
|
| Humans | 73 | 2022 | 86643 | 0.810 |
Why?
|
| Retrospective Studies | 19 | 2022 | 8489 | 0.780 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 4 | 2018 | 91 | 0.760 |
Why?
|
| Severity of Illness Index | 3 | 2016 | 1801 | 0.750 |
Why?
|
| Inpatients | 2 | 2020 | 297 | 0.740 |
Why?
|
| Decision Support Techniques | 2 | 2021 | 160 | 0.730 |
Why?
|
| Prospective Studies | 16 | 2022 | 4213 | 0.720 |
Why?
|
| Myocardial Contraction | 1 | 2021 | 244 | 0.720 |
Why?
|
| Length of Stay | 4 | 2018 | 702 | 0.720 |
Why?
|
| Prenatal Care | 1 | 2020 | 72 | 0.720 |
Why?
|
| Female | 37 | 2022 | 44532 | 0.700 |
Why?
|
| Adult | 27 | 2021 | 25648 | 0.690 |
Why?
|
| Aspirin | 1 | 2020 | 156 | 0.680 |
Why?
|
| Palpation | 1 | 2018 | 18 | 0.680 |
Why?
|
| Critical Illness | 2 | 2019 | 294 | 0.670 |
Why?
|
| Biomarkers | 7 | 2021 | 1718 | 0.670 |
Why?
|
| Respiratory Insufficiency | 1 | 2020 | 150 | 0.650 |
Why?
|
| Publication Bias | 1 | 2017 | 13 | 0.620 |
Why?
|
| Fluid Therapy | 1 | 2018 | 50 | 0.620 |
Why?
|
| Lung Injury | 1 | 2018 | 47 | 0.610 |
Why?
|
| Pregnancy Complications | 3 | 2017 | 336 | 0.610 |
Why?
|
| Editorial Policies | 1 | 2017 | 32 | 0.600 |
Why?
|
| Endoglin | 1 | 2017 | 20 | 0.600 |
Why?
|
| Aortic Aneurysm | 1 | 2017 | 80 | 0.590 |
Why?
|
| Biostatistics | 1 | 2017 | 20 | 0.590 |
Why?
|
| Blood Loss, Surgical | 1 | 2017 | 112 | 0.590 |
Why?
|
| Databases, Factual | 5 | 2018 | 814 | 0.590 |
Why?
|
| Pain, Postoperative | 2 | 2019 | 240 | 0.580 |
Why?
|
| Blood Transfusion | 1 | 2017 | 157 | 0.580 |
Why?
|
| Hospital Mortality | 2 | 2018 | 349 | 0.570 |
Why?
|
| Evidence-Based Medicine | 2 | 2021 | 429 | 0.570 |
Why?
|
| Angiogenic Proteins | 1 | 2016 | 17 | 0.560 |
Why?
|
| Young Adult | 11 | 2020 | 5976 | 0.550 |
Why?
|
| Echocardiography, Three-Dimensional | 5 | 2015 | 516 | 0.550 |
Why?
|
| Pharmacogenomic Testing | 3 | 2021 | 97 | 0.520 |
Why?
|
| Heart | 3 | 2017 | 539 | 0.520 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2017 | 208 | 0.520 |
Why?
|
| Pharmacogenetics | 5 | 2022 | 434 | 0.510 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2019 | 865 | 0.510 |
Why?
|
| Hospitals, High-Volume | 1 | 2015 | 35 | 0.500 |
Why?
|
| Hypertension | 3 | 2018 | 1141 | 0.500 |
Why?
|
| Pregnancy Outcome | 4 | 2018 | 247 | 0.490 |
Why?
|
| Endovascular Procedures | 1 | 2017 | 218 | 0.490 |
Why?
|
| Research Design | 1 | 2018 | 594 | 0.490 |
Why?
|
| Aortic Valve Stenosis | 2 | 2012 | 131 | 0.480 |
Why?
|
| Echocardiography, Transesophageal | 7 | 2018 | 344 | 0.480 |
Why?
|
| Risk Factors | 10 | 2021 | 5417 | 0.470 |
Why?
|
| Hospitals | 2 | 2021 | 294 | 0.460 |
Why?
|
| Heart-Assist Devices | 1 | 2019 | 731 | 0.420 |
Why?
|
| Hospitalization | 2 | 2015 | 849 | 0.420 |
Why?
|
| Anesthesia | 3 | 2022 | 164 | 0.390 |
Why?
|
| Adolescent | 9 | 2018 | 8981 | 0.390 |
Why?
|
| Aged | 16 | 2019 | 18415 | 0.380 |
Why?
|
| Aged, 80 and over | 8 | 2018 | 6509 | 0.380 |
Why?
|
| Case-Control Studies | 4 | 2020 | 1805 | 0.380 |
Why?
|
| Cardiac Surgical Procedures | 5 | 2018 | 462 | 0.360 |
Why?
|
| Cohort Studies | 6 | 2018 | 2767 | 0.350 |
Why?
|
| United States | 7 | 2019 | 6672 | 0.350 |
Why?
|
| Treatment Outcome | 8 | 2022 | 7993 | 0.340 |
Why?
|
| Heart Failure | 1 | 2018 | 1204 | 0.340 |
Why?
|
| Multivariate Analysis | 3 | 2017 | 999 | 0.330 |
Why?
|
| Middle Aged | 14 | 2019 | 25028 | 0.330 |
Why?
|
| Image Enhancement | 1 | 2012 | 563 | 0.330 |
Why?
|
| Internship and Residency | 5 | 2019 | 1004 | 0.300 |
Why?
|
| Operating Rooms | 2 | 2019 | 126 | 0.300 |
Why?
|
| Intra-Aortic Balloon Pumping | 2 | 2019 | 78 | 0.290 |
Why?
|
| Male | 20 | 2022 | 40965 | 0.290 |
Why?
|
| Vasoconstrictor Agents | 2 | 2017 | 53 | 0.290 |
Why?
|
| Time Factors | 3 | 2021 | 5210 | 0.290 |
Why?
|
| Logistic Models | 4 | 2017 | 1186 | 0.270 |
Why?
|
| Predictive Value of Tests | 4 | 2021 | 1673 | 0.270 |
Why?
|
| Intensive Care Units | 2 | 2019 | 373 | 0.260 |
Why?
|
| Clinical Competence | 4 | 2016 | 751 | 0.260 |
Why?
|
| Mitral Valve Insufficiency | 3 | 2011 | 187 | 0.260 |
Why?
|
| Curriculum | 3 | 2019 | 539 | 0.260 |
Why?
|
| Communication | 2 | 2019 | 441 | 0.240 |
Why?
|
| Labor, Obstetric | 2 | 2022 | 46 | 0.240 |
Why?
|
| Cesarean Section | 3 | 2018 | 137 | 0.230 |
Why?
|
| Postoperative Complications | 5 | 2020 | 2207 | 0.230 |
Why?
|
| Sex Work | 1 | 2002 | 12 | 0.230 |
Why?
|
| Preoperative Care | 2 | 2017 | 397 | 0.220 |
Why?
|
| Prognosis | 4 | 2021 | 3679 | 0.210 |
Why?
|
| Monitoring, Intraoperative | 3 | 2018 | 109 | 0.210 |
Why?
|
| Tramadol | 1 | 2022 | 14 | 0.210 |
Why?
|
| Analgesia, Obstetrical | 1 | 2022 | 21 | 0.210 |
Why?
|
| Breast Feeding | 2 | 2002 | 91 | 0.210 |
Why?
|
| Postnatal Care | 2 | 2021 | 25 | 0.210 |
Why?
|
| Analgesia, Epidural | 1 | 2022 | 38 | 0.200 |
Why?
|
| Mitral Valve | 3 | 2012 | 248 | 0.200 |
Why?
|
| Follow-Up Studies | 4 | 2021 | 3640 | 0.200 |
Why?
|
| Respiratory System | 1 | 2022 | 116 | 0.200 |
Why?
|
| Pharmacogenomic Variants | 1 | 2021 | 41 | 0.200 |
Why?
|
| Airway Management | 1 | 2022 | 46 | 0.200 |
Why?
|
| Anesthetics | 1 | 2021 | 48 | 0.200 |
Why?
|
| Placenta Growth Factor | 2 | 2018 | 70 | 0.190 |
Why?
|
| Follistatin-Related Proteins | 1 | 2020 | 6 | 0.190 |
Why?
|
| Follistatin | 1 | 2020 | 7 | 0.190 |
Why?
|
| Workload | 1 | 2021 | 128 | 0.190 |
Why?
|
| Intubation, Intratracheal | 1 | 2022 | 144 | 0.190 |
Why?
|
| Elective Surgical Procedures | 1 | 2021 | 116 | 0.190 |
Why?
|
| Placenta | 1 | 2022 | 175 | 0.190 |
Why?
|
| Analgesics | 1 | 2021 | 119 | 0.190 |
Why?
|
| Seasons | 1 | 2021 | 223 | 0.190 |
Why?
|
| Anesthesia Department, Hospital | 1 | 2019 | 8 | 0.180 |
Why?
|
| Incidence | 3 | 2018 | 1577 | 0.180 |
Why?
|
| Transportation of Patients | 1 | 2019 | 32 | 0.180 |
Why?
|
| Antibodies, Viral | 1 | 2021 | 293 | 0.170 |
Why?
|
| Clinical Decision-Making | 2 | 2021 | 257 | 0.170 |
Why?
|
| Workflow | 1 | 2019 | 77 | 0.170 |
Why?
|
| Pneumonia, Aspiration | 1 | 2018 | 19 | 0.170 |
Why?
|
| Hepatitis C Antibodies | 1 | 1998 | 8 | 0.170 |
Why?
|
| Neuromuscular Blockade | 1 | 2018 | 26 | 0.170 |
Why?
|
| Reproducibility of Results | 2 | 2017 | 2705 | 0.170 |
Why?
|
| Neuromuscular Blocking Agents | 1 | 2018 | 29 | 0.170 |
Why?
|
| Ultrasonography, Interventional | 2 | 2016 | 121 | 0.170 |
Why?
|
| Down-Regulation | 1 | 2020 | 504 | 0.160 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2019 | 103 | 0.160 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 1998 | 44 | 0.160 |
Why?
|
| Carrier State | 1 | 1998 | 39 | 0.160 |
Why?
|
| Drug Administration Schedule | 1 | 2020 | 916 | 0.160 |
Why?
|
| Pregnancy Trimester, Third | 1 | 2018 | 70 | 0.160 |
Why?
|
| Intraoperative Care | 1 | 2018 | 82 | 0.160 |
Why?
|
| Rats | 2 | 2022 | 3990 | 0.160 |
Why?
|
| Pain Management | 1 | 2019 | 127 | 0.160 |
Why?
|
| Oxytocics | 1 | 2018 | 24 | 0.160 |
Why?
|
| Leukocytosis | 1 | 2017 | 16 | 0.160 |
Why?
|
| Pregnancy Trimester, Second | 1 | 2017 | 66 | 0.150 |
Why?
|
| Maternal Health Services | 1 | 2017 | 16 | 0.150 |
Why?
|
| Cystectomy | 1 | 2018 | 102 | 0.150 |
Why?
|
| Hospital Costs | 1 | 2018 | 105 | 0.150 |
Why?
|
| Heart Rate | 2 | 2017 | 492 | 0.150 |
Why?
|
| Oxytocin | 1 | 2018 | 71 | 0.150 |
Why?
|
| Maternal Mortality | 1 | 2017 | 15 | 0.150 |
Why?
|
| Prevalence | 2 | 2018 | 1239 | 0.150 |
Why?
|
| Coronary Artery Disease | 1 | 2022 | 350 | 0.150 |
Why?
|
| Bradycardia | 1 | 2017 | 39 | 0.150 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2019 | 199 | 0.150 |
Why?
|
| Chi-Square Distribution | 1 | 2017 | 364 | 0.150 |
Why?
|
| Robotic Surgical Procedures | 1 | 2022 | 267 | 0.140 |
Why?
|
| Ultrasonography, Prenatal | 1 | 2017 | 152 | 0.140 |
Why?
|
| Postoperative Care | 1 | 2017 | 221 | 0.140 |
Why?
|
| Ultrasonography | 1 | 2018 | 695 | 0.140 |
Why?
|
| Protamines | 1 | 2015 | 8 | 0.140 |
Why?
|
| Hepatitis C | 1 | 1998 | 208 | 0.140 |
Why?
|
| Hemodynamics | 2 | 2018 | 710 | 0.140 |
Why?
|
| Sensitivity and Specificity | 2 | 2021 | 1991 | 0.140 |
Why?
|
| Infant, Newborn | 3 | 2012 | 2379 | 0.130 |
Why?
|
| Puerperal Disorders | 1 | 2015 | 32 | 0.130 |
Why?
|
| Odds Ratio | 1 | 2017 | 678 | 0.130 |
Why?
|
| Child | 2 | 2020 | 6927 | 0.130 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2016 | 376 | 0.130 |
Why?
|
| Coronary Artery Bypass | 2 | 2022 | 228 | 0.130 |
Why?
|
| Computer Simulation | 4 | 2016 | 1078 | 0.130 |
Why?
|
| Gestational Age | 1 | 2016 | 311 | 0.130 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 316 | 0.130 |
Why?
|
| Comorbidity | 1 | 2018 | 943 | 0.130 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 301 | 0.130 |
Why?
|
| Hospitals, Urban | 1 | 2015 | 54 | 0.130 |
Why?
|
| Thoracic Surgery | 1 | 2015 | 43 | 0.120 |
Why?
|
| Pilot Projects | 2 | 2018 | 839 | 0.120 |
Why?
|
| HIV Infections | 1 | 2002 | 772 | 0.120 |
Why?
|
| Cardiovascular Diseases | 1 | 2021 | 827 | 0.120 |
Why?
|
| Demography | 1 | 2014 | 177 | 0.120 |
Why?
|
| Risk Assessment | 2 | 2021 | 2261 | 0.120 |
Why?
|
| Survival Analysis | 1 | 2017 | 1538 | 0.120 |
Why?
|
| Learning | 1 | 2016 | 280 | 0.110 |
Why?
|
| Heart Valve Prosthesis Implantation | 2 | 2011 | 166 | 0.110 |
Why?
|
| User-Computer Interface | 2 | 2011 | 185 | 0.110 |
Why?
|
| Neuropeptide Y | 1 | 2012 | 31 | 0.110 |
Why?
|
| Patient Care Team | 1 | 2015 | 280 | 0.110 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 2012 | 30 | 0.110 |
Why?
|
| Academic Medical Centers | 1 | 2015 | 379 | 0.110 |
Why?
|
| Coronary Circulation | 1 | 2012 | 130 | 0.100 |
Why?
|
| Heart Arrest | 1 | 2015 | 265 | 0.100 |
Why?
|
| Coronary Vessel Anomalies | 1 | 2012 | 41 | 0.100 |
Why?
|
| Pulmonary Edema | 1 | 2011 | 50 | 0.100 |
Why?
|
| Tricuspid Valve Stenosis | 1 | 2011 | 4 | 0.100 |
Why?
|
| Hypercholesterolemia | 1 | 2012 | 161 | 0.100 |
Why?
|
| Myocardial Ischemia | 1 | 2012 | 162 | 0.100 |
Why?
|
| Ventricular Outflow Obstruction | 1 | 2011 | 21 | 0.100 |
Why?
|
| Saphenous Vein | 1 | 2011 | 61 | 0.100 |
Why?
|
| Succinylcholine | 2 | 2022 | 14 | 0.100 |
Why?
|
| Aneurysm, False | 1 | 2011 | 54 | 0.100 |
Why?
|
| Abnormalities, Multiple | 1 | 2012 | 232 | 0.090 |
Why?
|
| Pulmonary Artery | 1 | 2012 | 306 | 0.090 |
Why?
|
| ROC Curve | 1 | 2012 | 752 | 0.090 |
Why?
|
| Water-Electrolyte Balance | 1 | 2010 | 66 | 0.090 |
Why?
|
| Neovascularization, Pathologic | 1 | 2012 | 353 | 0.090 |
Why?
|
| Aortic Valve | 1 | 2011 | 222 | 0.090 |
Why?
|
| Coronary Disease | 1 | 2011 | 261 | 0.090 |
Why?
|
| Teaching | 1 | 2010 | 147 | 0.090 |
Why?
|
| Animals | 5 | 2022 | 26582 | 0.090 |
Why?
|
| Myocardial Infarction | 1 | 2011 | 376 | 0.080 |
Why?
|
| Point-of-Care Systems | 2 | 2019 | 141 | 0.060 |
Why?
|
| Chicago | 2 | 2020 | 1379 | 0.060 |
Why?
|
| Disease Models, Animal | 3 | 2019 | 2232 | 0.060 |
Why?
|
| Fetal Distress | 1 | 2002 | 7 | 0.060 |
Why?
|
| Infant Welfare | 1 | 2002 | 6 | 0.060 |
Why?
|
| Electrocardiography | 2 | 2018 | 478 | 0.050 |
Why?
|
| Omeprazole | 1 | 2022 | 11 | 0.050 |
Why?
|
| Hydralazine | 1 | 2022 | 20 | 0.050 |
Why?
|
| Bupivacaine | 1 | 2022 | 45 | 0.050 |
Why?
|
| Florida | 1 | 2021 | 55 | 0.050 |
Why?
|
| HIV-1 | 1 | 2002 | 163 | 0.050 |
Why?
|
| Oxycodone | 1 | 2022 | 35 | 0.050 |
Why?
|
| Fentanyl | 1 | 2022 | 65 | 0.050 |
Why?
|
| Texas | 1 | 2021 | 101 | 0.050 |
Why?
|
| Evidence-Based Practice | 1 | 2021 | 45 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2011 | 2601 | 0.050 |
Why?
|
| Anesthetics, Local | 1 | 2022 | 76 | 0.050 |
Why?
|
| Age Distribution | 1 | 2021 | 204 | 0.050 |
Why?
|
| Image Processing, Computer-Assisted | 3 | 2012 | 1204 | 0.050 |
Why?
|
| Fever | 1 | 2022 | 125 | 0.050 |
Why?
|
| Cross Reactions | 1 | 2021 | 106 | 0.050 |
Why?
|
| Immunoglobulin M | 1 | 2021 | 154 | 0.050 |
Why?
|
| Insurance, Health | 1 | 2021 | 160 | 0.050 |
Why?
|
| New York City | 1 | 2020 | 59 | 0.050 |
Why?
|
| Washington | 1 | 2020 | 48 | 0.050 |
Why?
|
| Coronary Angiography | 2 | 2012 | 232 | 0.050 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 30 | 0.050 |
Why?
|
| Personnel, Hospital | 1 | 2020 | 30 | 0.050 |
Why?
|
| Laboratories | 1 | 2020 | 43 | 0.050 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2020 | 73 | 0.050 |
Why?
|
| Pulsatile Flow | 1 | 2019 | 49 | 0.040 |
Why?
|
| Health Resources | 1 | 2020 | 76 | 0.040 |
Why?
|
| Pain | 1 | 2022 | 391 | 0.040 |
Why?
|
| Health Status Disparities | 1 | 2021 | 170 | 0.040 |
Why?
|
| Atracurium | 1 | 2018 | 5 | 0.040 |
Why?
|
| Reference Values | 1 | 2020 | 674 | 0.040 |
Why?
|
| Immunoglobulin G | 1 | 2021 | 456 | 0.040 |
Why?
|
| Colostrum | 1 | 1998 | 2 | 0.040 |
Why?
|
| Milk, Human | 1 | 1998 | 43 | 0.040 |
Why?
|
| Simulation Training | 1 | 2019 | 88 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2021 | 1019 | 0.040 |
Why?
|
| Fetal Blood | 1 | 1998 | 90 | 0.040 |
Why?
|
| Organ Dysfunction Scores | 1 | 2018 | 27 | 0.040 |
Why?
|
| Uterus | 1 | 2019 | 215 | 0.040 |
Why?
|
| Therapeutics | 1 | 2017 | 12 | 0.040 |
Why?
|
| Ischemia | 1 | 2019 | 243 | 0.040 |
Why?
|
| Leukocyte Count | 1 | 2017 | 220 | 0.040 |
Why?
|
| Hepacivirus | 1 | 1998 | 159 | 0.040 |
Why?
|
| RNA, Viral | 1 | 1998 | 327 | 0.040 |
Why?
|
| Perinatal Care | 1 | 2017 | 18 | 0.040 |
Why?
|
| Pneumonia | 1 | 2018 | 179 | 0.040 |
Why?
|
| APACHE | 1 | 2016 | 21 | 0.040 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2018 | 187 | 0.040 |
Why?
|
| Software | 2 | 2011 | 654 | 0.040 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2019 | 1219 | 0.040 |
Why?
|
| Morbidity | 1 | 2017 | 148 | 0.040 |
Why?
|
| Diagnosis, Differential | 2 | 2011 | 1565 | 0.040 |
Why?
|
| Propensity Score | 1 | 2017 | 136 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 1998 | 879 | 0.040 |
Why?
|
| Lung Diseases | 1 | 2018 | 263 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2018 | 567 | 0.030 |
Why?
|
| Pregnancy Proteins | 1 | 2015 | 38 | 0.030 |
Why?
|
| Pregnancy in Diabetics | 1 | 2015 | 37 | 0.030 |
Why?
|
| Diabetes, Gestational | 1 | 2015 | 39 | 0.030 |
Why?
|
| Delphi Technique | 1 | 2015 | 80 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2019 | 535 | 0.030 |
Why?
|
| Precision Medicine | 1 | 2019 | 395 | 0.030 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2015 | 148 | 0.030 |
Why?
|
| Models, Anatomic | 1 | 2015 | 91 | 0.030 |
Why?
|
| Aorta | 1 | 2015 | 280 | 0.030 |
Why?
|
| Attitude of Health Personnel | 1 | 2019 | 636 | 0.030 |
Why?
|
| Pandemics | 1 | 2020 | 740 | 0.030 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2019 | 582 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2018 | 1961 | 0.030 |
Why?
|
| Consensus | 1 | 2015 | 335 | 0.030 |
Why?
|
| Echocardiography, Four-Dimensional | 1 | 2012 | 1 | 0.030 |
Why?
|
| Educational Measurement | 1 | 2015 | 225 | 0.030 |
Why?
|
| Receptors, Neuropeptide Y | 1 | 2012 | 3 | 0.030 |
Why?
|
| Bromocriptine | 1 | 2012 | 12 | 0.030 |
Why?
|
| Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 1 | 2012 | 16 | 0.030 |
Why?
|
| Education, Medical, Graduate | 1 | 2016 | 369 | 0.030 |
Why?
|
| Rupture, Spontaneous | 1 | 2011 | 43 | 0.030 |
Why?
|
| Infant | 1 | 1998 | 3046 | 0.030 |
Why?
|
| Systole | 1 | 2011 | 129 | 0.030 |
Why?
|
| Neovascularization, Physiologic | 1 | 2012 | 133 | 0.030 |
Why?
|
| Ventricular Function, Right | 1 | 2012 | 142 | 0.030 |
Why?
|
| Swine | 1 | 2012 | 555 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 2012 | 297 | 0.020 |
Why?
|
| Oxygen | 1 | 2015 | 726 | 0.020 |
Why?
|
| Surgeons | 1 | 2015 | 238 | 0.020 |
Why?
|
| Anesthesia, General | 1 | 2011 | 114 | 0.020 |
Why?
|
| Computer Graphics | 1 | 2010 | 100 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2019 | 2271 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2012 | 407 | 0.020 |
Why?
|
| Catheterization | 1 | 2011 | 232 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2012 | 860 | 0.020 |
Why?
|
| Myocardium | 1 | 2012 | 529 | 0.020 |
Why?
|
| Myocytes, Cardiac | 1 | 2012 | 275 | 0.020 |
Why?
|
| Trans-Activators | 1 | 2012 | 429 | 0.020 |
Why?
|
| Cardiac Catheterization | 1 | 2011 | 291 | 0.020 |
Why?
|
| Respiratory Mechanics | 1 | 2010 | 102 | 0.020 |
Why?
|
| Obesity | 1 | 2015 | 963 | 0.020 |
Why?
|
| Reoperation | 1 | 2011 | 597 | 0.020 |
Why?
|
| Monitoring, Physiologic | 1 | 2010 | 268 | 0.020 |
Why?
|
| Physicians | 1 | 2016 | 673 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2016 | 2501 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2012 | 1924 | 0.020 |
Why?
|
| Respiration, Artificial | 1 | 2010 | 334 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2012 | 1565 | 0.020 |
Why?
|
| Mice | 1 | 2012 | 11352 | 0.010 |
Why?
|